TimesSquare Capital Management LLC lowered its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 2.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 451,900 shares of the company’s stock after selling 12,700 shares during the period. TimesSquare Capital Management LLC’s holdings in Tarsus Pharmaceuticals were worth $14,565,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the company. Frazier Management LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth $79,236,000. BlackRock Inc. grew its holdings in Tarsus Pharmaceuticals by 5.4% during the 1st quarter. BlackRock Inc. now owns 339,797 shares of the company’s stock valued at $10,952,000 after purchasing an additional 17,374 shares in the last quarter. Sands Capital Management LLC acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at $10,746,000. Northern Trust Corp acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at $2,909,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at $1,539,000. 62.19% of the stock is owned by institutional investors.
Tarsus Pharmaceuticals stock opened at $38.59 on Friday. The business has a 50-day simple moving average of $31.05. Tarsus Pharmaceuticals, Inc. has a 1 year low of $15.32 and a 1 year high of $63.69. The company has a market cap of $792.02 million and a P/E ratio of -8.93.
In other news, major shareholder Rtw Investments, Lp sold 450,000 shares of the firm’s stock in a transaction dated Friday, May 7th. The shares were sold at an average price of $29.98, for a total value of $13,491,000.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Separately, Zacks Investment Research raised shares of Tarsus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, April 29th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $37.25.
Tarsus Pharmaceuticals Profile
Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Story: What Is Dividend Yield and How Do You Calculate It?
Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.